In this study, PEGylated IL-29 (PEG-rIL-29) treatment was found to improve survival, reduce GVHD severity, and enhance epithelial proliferation and ISC-derived organoid growth after allo-HSCT (101). Here, IFNL1 is linked to graft versus host disease.